HEART FAILURE INFUSION SERVICES ENROLLMENT/ORDER FORM										
Fax completed form, insurance information, and clinical documentation to:										
	Patient Name:						Date	Date of Birth:		
	Address:									
option care health	Phone: Height:					☐ inches ☐ cm Weight:		Weight:	☐ lbs ☐ kg	
Clinical Information										
Primary Diagnosis De	escription:						ICD-10 Code:			
Allergies:				□ NK	DA DNR Status: Order Received N/A					
Plan of Care: ☐ Bridge to Transplant ☐ Bridge to VAD ☐ Bridge to Decision ☐ Palliative										
Prescription and Orders										
☐ Milrinone						Continuously via ambulatory infusion pump				
☐ Dobutamine☐ Dopamine		 				Continuously via ambulatory infusion pump Continuously via ambulatory infusion pump				
	Administer mcg/kg/min Continuously via amb Notify MD of wt. gain: 2 lbs./day or 5 lbs./wk.; BP < > > >									
Dosing weight: (if different than actual	_ □ lbs. □ kg weiaht)	Notify MD of wt. gain: \square 2 lbs./day or 5 lbs./wk.; BP < > HR < > Adjust dose and rate only if weight changes by > 10 lbs.								
Access: PICC Tunneled Catheter Implanted Port Other: # of Lumens:										
☐ Additional Orders:										
☐ Lab Orders: ☐ BN				Call/Fav. gazzilta ta						
Frequency:			CBC				Call/Fax results to:			
 Instruct/Teach: DO NOT routinely flush lumen used for continuous inotrope infusion. Initiate/maintain peripheral IV prn for CVAD troubleshooting (milrinone and/or dobutamine only), DO NOT INFUSE DOPAMINE PERIPHERALLY Indicate appropriate flushing protocol by checking the appropriate item(s) Provide all supplies necessary to instruct patient/caregiver on overall heart failure therapy administration and management. Alteplase (Cathflo) 2mg per lumen to dwell, may dispense and repeat x 1 per incident of sluggish/occluded line. Qty: #2 Skilled nurse to train patient/caregiver to self- administer medication, access/maintain central IV access (where applicable), monitor, and treat ADRs and PRN visits for additional patient needs r/t therapy, VAD, and education 										
Indicated Access Devi	ce to be Utilized	NS Flush (0.9% NaCl)				Н	Heparin			
☐ Peripheral IV ***When required, f and/or dobutamin		☐ 2-3 mL pre/post infusion; maintenance 2-3 mL every 12 hours				2 🗆	□ N/A □ 1-3 mL heparin (10 units/mL) every 24 hours			
☐ PICC & Central Turturneled	nneled & Non-	☐ 5 ml pre/post use; 5 ml pre/10 ml post lab draw				24	☐ 3 - 5 ml (heparin 10 units/ml) post use or every 24 hours if not used			
☐ Implanted Port	☐ 5 - 10 ml pre/post infusion ☐ 10 - 20 ml pre/ post lab draw ☐					☐ ☐ 3 - 5 ml (heparin 100 units/ml) post-use or every 24 hours if accessed but not used ☐ 3 - 5 ml (heparin 100 units/ml) flush weekly to monthly if not accessed.				
☐ Valved Catheters: Midline		☐ 5 - 10 ml pre/post use ☐ 10 - 20 ml pre/post lab draw; maintenance 5 - 10 ml at least weekly					N/A			
I certify that the use of the indicated treatment is medically necessary, and I will be supervising the patient's treatment.										
Prescriber Signature: Date:								Date:		
Prescriber Name:			Prescriber Information Phone:				Fax:			
Address:			NPI:				l			
City, State: Zip:				Office Contact:						
CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that do not require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/nation tall thorization is										

CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that do not require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure of failure to maintain confidentiality could subject you to penalties described in federal and state laws. IMPORTANT WARNING: This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.